Google DeepMind Spinout Isomorphic Labs Seeks Funding at $40–$50 Billion Valuation

Isomorphic Labs, the AI drug discovery company spun out of Google DeepMind, is in early talks to raise new funding at a valuation of at least $40 billion and potentially as high as $50 billion, according to Bloomberg. The round would close just five months after the company raised a $2.1 billion Series B — and before a single AI-designed drug has entered human trials.

Why it matters: A $40–50 billion valuation for a pre-clinical drug discovery company would rank among the largest bets ever placed on AI in healthcare, testing how far capital markets will go on potential rather than proof.

Background

Isomorphic Labs was spun out of Google DeepMind in 2021, inheriting the research behind AlphaFold — the AI system that predicted the 3D structure of nearly every known protein and earned DeepMind co-founder Demis Hassabis a share of the 2024 Nobel Prize in Chemistry. Hassabis leads both DeepMind and Isomorphic Labs.

The company's central thesis: if AlphaFold can model how proteins fold, the same approach can model how drug molecules interact with those proteins — dramatically compressing a process that typically takes more than a decade. Isomorphic has signed research partnerships with Eli Lilly and Novartis to validate the approach at commercial scale.

The Numbers

• Series B (May 2026): $2.1 billion at a reported valuation around $6 billion
• Proposed round (October 2026): At least $40 billion, up to $50 billion
• Valuation jump: Roughly 7–8× in five months
• Clinical status: No AI-designed Isomorphic drugs in human trials

That 7–8× jump in under six months demands scrutiny. Isomorphic has not disclosed specific results from its Lilly or Novartis partnerships. Drug discovery timelines mean that even successful AI-assisted candidate identification could take years to yield compounds ready for human testing — let alone approval.

What This Means

For the AI health sector, a successful round at this valuation sets a new precedent: investors are willing to price in outcomes that are years, possibly a decade, away. That can accelerate capital formation across the space, but it also inflates expectations beyond what current science can yet support.

For competing AI drug discovery firms — including Recursion Pharmaceuticals and Insilico Medicine — a $40–50 billion Isomorphic signals that the premium is going to companies with deep model provenance. In Isomorphic's case, that means AlphaFold's scientific credibility and Google DeepMind's research heritage, not necessarily the most clinical progress.

For the broader biotech investment cycle, the round arrives during a period when AI-linked valuations across sectors have risen sharply. Whether that context is tailwind or warning sign depends on what Isomorphic discloses before the round closes.

What to Watch

Whether the round closes at the reported valuation, and whether Isomorphic announces any partnership results or candidate milestones alongside the raise. Any disclosure of clinical progress — even early-stage candidate identification — would add concrete substance to a valuation that currently rests almost entirely on model capability and institutional pedigree. Without it, the round will be scrutinized as a bet on brand, not biology.